

* Risk Factors for atherosclerosis :-

- 1] Smoking :- i) Most crucial yet preventable risk factor for CAD [significant smoking → 2-3 packs for 10 yrs]
 ii) Also risk factor for Renal artery Stenosis & Peripheral vascular disease

2] Hypertension :- $\geq 140/90$

3] Hypercholesterolemia :- i) do hs-CRP $\text{if } \oplus$ → do Lp(a) & Homocysteine

ii) Apo B₁₀₀ / HDL ratio

iii) Low HDL-2

⇒ High LDL > Low HDL as a risk factor

iv) High LDL

v) Total chol/HDL ratio

⇒ Start statins only if :- a) Clinical atherosclerosis

[40 mg Atorvastatin] b) DM (40-75 yrs of age)
 ◊ LDL $> 190 \text{ mg/dL}$


4) DM \oplus ⇒ Insulin resistance (Abdominal obesity)

5) Family h/o premature CVD

6) Males (45 yrs) $>$ Females (55 yrs)
 present \in chest pain No chest pain (atypical symptom) } In India age $\Rightarrow 45-55$ yrs &
 F $>$ M & atypical presentation

7) Obesity & Metabolic syndrome

8) Malnutrition - Inflammation related - Atherosclerosis



* Hibernating myocardium :- Areas of myocardium which are persistently underperfused but still viable
 * stunned myocardium :- segmental dysfunction which persists for variable period of time after reperfusion

* Myocardial Ischemia
 ↗ Infarction
 ↗ Chronic Ischemia → Persistent ischemic dysfunction → Hibernating myocardium
 ↗ Salvaged → Transient post-ischemic dysfunction → stunned myocardium

* HOPE trial demonstrates that 'Ramipril' reduces fatal & non-fatal vascular events in high risk patients

* Although ACE \ominus & ARB's are equally effective, it's better to start ACE \ominus as ARB's tend to ↑ AT-2 receptor which prone for malignancy like esophageal carcinoma

⇒ ACE \ominus are C/I in :- Pregnancy, Hereditary angioedema, B/L Renal artery stenosis


⇒ Stop ACE \ominus if serum creatinine $> 30\%$ from Baseline \in in 2 wk of starting ACE \ominus or if Hyperkalemia develops

* Perfusion scintigraphy/MRI :- can distinguish betwⁿ stunned myocardium from scarred tissue

* Electron Beam CT :- Quantify Cardiac Calcification

* Agatston score :- To measure degree of coronary artery calcification using Hounsfield Units (\uparrow unit \propto \uparrow density of calcification)


* Intravenous ultrasound :- IOC for ostial left main lesion & coronary dissection



* Prinzmetal angina / vasospastic angina :-

- i) Chest pain at Rest for 5-15 mins (relieved by sublingual NTG)
- ii) Recurrent episodes (↑ in Midnight - early morning)
- iii) During the episode → Tachycardia, HTN, sweating (Diaphoresis)
- iv) Patient is usually a smoker
- v) Transient ST segment elevation (+) during the episode, Angiography is @ ← Gold std. for diagnosis
- vi) Ca²⁺ ⊕ [Diltiazem] is DOC, but not ⊕ cor of vasospasm
- vii) Provocation tests can be used to confirm diagnosis (Hyperventilation, Cold pressor test, Intracoronary acetylcholine challenge test, ergometrine)

* Chronic Stable Angina :-



i) These patients have angina on exertion :- Look for Inducible Ischemia via:-

a) Treadmill stress test or Exercise ECG or Bruce protocol treadmill test :-

i) significant :- If Downslloping ST segment depression of >2mm in 6min before achieving max Heart Rate [HRmax = 220 - Age]

2) C/I :-

Absolute Contraindications to exercise testing:

- Acute myocardial infarction (within 6 days)
- High-risk unstable angina
- Uncontrolled cardiac arrhythmia with hemodynamic compromise
- Active endocarditis
- Symptomatic severe aortic stenosis
- Decompensated heart failure
- Acute pulmonary embolism or pulmonary infarction
- Acute myocarditis or pericarditis
- Severe pulmonary hypertension
- Aortic dissection

b) Myocardial perfusion scanning :-

i) Done if :- Can't perform exercise test / Can't interpret results

or dobutamine

ii) PET scan (I₁₅₃), iii) Thallium 201 ,

iv) MRI (IOC for ventricular funcⁿ),

v) Dobutamine echocardiography

3) Result → If perfusion defect during stress but not at rest = Reversible Myocardial Ischemia

→ Persistent perfusion defect during both phases = Previous MI

Rx :- Sublingual NTG → 0.3 to 0.6 mg, 3 tabs in 20 mins Not responding → STEMI, NSTEMI, Unstable Angina } limitation to Nitrates ⇒ TOLERANCE ⇒ Nitrate free 8-12 hrs daily

[Other long acting oral Nitrates → Isosorbide dinitrate & mononitrate]

MoA of Nitrates :- i) vasodilation $\rightarrow \downarrow \text{BP} \rightarrow \downarrow \text{Afterload}$ $\downarrow \text{O}_2 \text{ consumption}$; ii) $\uparrow \text{O}_2 \text{ supply to Heart by Coronary vasodilation}$ $\downarrow \text{Venous return} \rightarrow \downarrow \text{Preload}$ by Heart

C/I :- i) C Phosphodiesterase 5 inhibitors [Sildenafil, Tadalafil, Vardenafil] → Severe Hypotension
ii) In HCM, severe AS, Constrictive pericarditis, closed angle glaucoma & Mitral stenosis

Pharmacologic Classes for Treatment of Angina			
Medication Class	Impact on HR	Impact on BP	Physiologic Mechanism
Beta Blockers	↓	↓	Decrease pump function
Calc Channel Blockers	↓	↓	Decrease Pump function + Vaso-dilation
Nitrates	↑	↑	Vaso-dilatation
Ranolazine	○	○	Reduced Cardiac Output

2nd line → i) $\beta\Theta$:- $\uparrow \text{O}_2 \text{ demand by Heart by } + \text{Heart rate} \& \text{ contractility}, \downarrow \text{BP}, \downarrow \text{apoptosis by Inhibiting Bradreceptors} \therefore \text{Prolong life post-MI}$

ii) CCB's :- Produce coronary & peripheral arterial dilation + ve inotropy & +ve conductivity \Rightarrow coz of -ve inotropy not to be used in Heart failure (uncompensated) & don't combine $\beta\Theta$ coz too much +HR & \downarrow contractility; Prefer Non DHP $>$ DHP coz No reflex tachycardia in Non-DHP (Verapamil / Diltiazem)

iii) Nicorandil :- K⁺ channel opener → vascular smooth muscle relaxation \Rightarrow Dilatation & prevent Intracellular Ca²⁺ toxicity

iv) Sibradin :- funny (I_F) channel Θ → Slows diastolic depolarisation & causes Bradycardia \Rightarrow No effect on contractility & can be combined \pm other drugs

v) Ranolazine :- It Θ late Na⁺ channel → Reduces cardiac stiffness, Does not affect HR, BP but prolongs exercise duration, metabolized by CYP3A4 & causes QT $\uparrow\uparrow$

[M. Ischemia \rightarrow ↑ late Na⁺ current \rightarrow Na⁺ overload \rightarrow Ca²⁺ overload \rightarrow ↑ Diastolic wall stiffness \rightarrow Intramural small vessel compression \rightarrow ↓ O₂ supply & ↑ O₂ demand] [CYP3A4 Θ shouldn't be given \pm it e.g. Ketoconazole, Grapefruit juice, Diltiazem, Verapamil, Macrolides & HIV protease Θ]

3rd line → i) Trimetazidine :- pFox Θ [O₂ req. of Glucose pathway is \downarrow than FFA pathway but During Ischemia FFA pathway used \therefore pFox Θ inhibits it & Resumes Glucose pathway]

ii) Fasudil (Rho kinase Θ) → causes Vasodilation





Table. Universal Definition of MI	
Type	Clinical and Diagnostic Criteria
1 Spontaneous MI	Plaque rupture, ulceration, fissuring, erosion, or dissection resulting in coronary thrombosis
2 Supply/demand mismatch	Mismatch between myocardial oxygen supply and demand driven by a secondary process other than coronary artery disease
3 Suspected MI-related death	Cardiac death in a setting suggestive of ischemic process without definitive cardiac biomarker evidence of MI
4a PCI-related MI	Rise in cardiac biomarkers accompanied by symptoms, electrocardiographic, angiographic, or imaging evidence of ischemia after PCI
4b Stent thrombosis	Confirmed stent thrombosis in context of ischemia and dynamic cardiac biomarker changes
5 CABG-related MI	Rise in cardiac biomarkers accompanied by symptoms, angiographic, or imaging evidence of ischemia after CABG

Abbreviations: CABG, coronary artery bypass graft; MI, myocardial infarction; PCI, percutaneous coronary intervention.


* Acute MI :- Evidence of Myocardial Necrosis [↑ Biomarkers] in the clinical setting of Ischemia + any one of the following changes :-

- i) New ST-T changes (Tall peaking Twaves followed by Twave inversions, ST segment elevation)
- ii) Symptoms of Ischemia
- iii) Pathological Q wave
- iv) Evidence of Thrombus by angiography
- v) Impaired perfusion on Scintigraphy

A transient midsystolic or late systolic apical murmur due to mitral regurgitation secondary to dysfunction of the mitral valve apparatus (papillary muscle dysfunction, LV dilation) may be present in STEMI.

* Cardiac Biomarkers :-

	Time to initial elevation	Mean time to peak elevation	Time to return to normal range
Myoglobin [fast to rise]	1-4 h	12 h	24 h
cTn [most sensitive to specific re-infarction]	4-8 h	24 h	48-72 h
cTn [re-infarction]	3-12 h	24 h	7-10 d
LDH [last to rise]	24 hours [tripled LDH/ ≥ 20]	3-6 days	2 weeks
SIGT [non-specific]	12 hours	48 hours	4-5 days



* General management → Confirm Diagnosis by :- → Specific Rx :-

- M :- Morphine
- O :- O₂ if ACS \pm satur $\leq 90\%$
- N :- Nitroglycerine
- A :- Aspirin
- C :- Clopidogrel/Ticagrelor [Pref]
- a) ECG
- b) Cardiac Biomarkers
- c) Killip classification/Forestier & Diamond
- d) Rx complications to look for LV failure

* AST → liver, skeletal muscle & cardiac muscle while ALT → liver specific \Rightarrow ↑ AST + Θ ALT :- Non Hepatological dis.

Like Rhabdomyolysis & MI [except Alcoholic hepatitis & Cirrhosis]

* Do Troponin I in case of Renal Failure & not T

* Reinfarction :- $\geq 20\%$ Increase in cTn / Absolute ↑ in cTn ($> 7 \text{ ng/L}$ over 2 hrs) value in 2nd sample obtained 3-6 hrs later

* Serum Myoglobin & Heart type fatty acid Binding protein [H-FABP] are smaller molecules that diffuse through interstitial fluids after cell death \Rightarrow ↑ 30 min after MI but are non-specific to myocardial tissue

Cardiac troponins

- Most specific cardiac biomarker for myocardial injury/acute MI
- Troponin elevations are useful for short & long-term prognosis in MI
- Cardiac troponin elevations correlate with estimation of infarct size and risk of death
- Newer highly sensitive assays for troponins become positive even within first 3 hours after onset of chest pain in MI

*J STEMI :-

Management :- CAB (circulation, Airway & Breathing) + ECG

Rx :- i) Aspirin (325mg stat; India → Dispirin (Dispersible) in Water) + Ticagrelor (180mg) / Clopidogrel (300mg oral) + Atorvastatin (80mg) → Together

(Statins used to stabilise plaque, Not for its HMGCoA reductase activity).

ii) Pain → Morphine (Not available in hospital) → Nitrates (0.5mg sublingual) shift to IV NTG infusion watch out for Hypotension

Then add β₁ (IV → Metoprolol 5mg repeat every 15-30 min) → β₁ are contraindicated in AV Block, Left ventricular failure & Bradycardia

TOC → Revascularisation Therapy (C/I → NSAIDs & Steroids co-occur interfere in Healing of Infarcted wall)

↳ 1^o Percutaneous Coronary Intervention (PCI) → Angiography + Angioplasty + Stent (1^o co-occur in ongoing MI) can only be done in CATH Lab if pt comes to a centre & NO PCI then do Thrombolysis/Fibrinolysis (Strepto, Uro, Tenoect, Reteplase & DSC whichever is available) → Strepto (1.5 million units in 100ml NS IV infusion over 1hr)

Bolus given as single infusion

* The door to balloon time is the time interval between the first medical contact & PCI. It is < 90min if patient is arriving in a hospital equipped for PCI & is < 120min for a pt. arriving in a hospital not equipped for PCI & is transported to where it can be done, if can't receive PCI in 120min do Thrombo/Fibrinolysis but rule out :- C/I → Past h/o haemorrhagic stroke, h/o non-haemorrhagic stroke in last 1yr, HTN at presentation of ≥ 180/110 mmHg, Suspected Aortic dissection, Any active internal bleeding (varices, bleeding peptic ulcer etc); There is 0.5-0.9% chance of Intracranial haemorrhage & allergic reaction (2%) → Take informed & written consent before giving Streptokinase. If he refuses then don't convince don't give the drug.

*J Thrombolysis is in 30min is as good as PCI

- II - III → in 1hr is 90% as good as PCI

- II - III → has good result in 2hrs [Golden Hour]

} 3-24 hrs after which PCI can be performed

Pharmacoinvasive Approach

*J Thrombolysis has no role > 12 hrs except if there are signs of ongoing Ischemia on ECG

*J/M/C Arrhythmia after reperfusion of an occluded coronary artery by fibrinolytic Rx :- Accelerated Sinoventricular Rhythm

* Tenoecteplase > streptokinase → ↑ Fibrin specificity & affinity, No allergic reaction, single bolus dose (0.5mg/kg) administration, Potency after 1hr → > 75% & ↓ Bleeding only S/E is ↑ chances of Intracranial Hemorrhage

* GIIb/IIIa antagonist given just before the procedure of PCI

* β₁ & ACE₂ to be given in 24 hrs → ↑ mortality

* Types of PCI :-

* Facilitated PCI = Thrombolysis followed by PCI → No longer Practised.

* Rescue PCI = Thrombolysed pt look for clinical improv (no pain) + More than 50% improvement in ST elevation betw 80-90min if not then its failed now do PCI (90min)

* Urgent PCI = Thrombolysis worked but pt suffers another MI (M/C in 1st 5 days) now don't thrombolyse again (C/I till 6m-1yr) now do PCI.

Characteristics of Fibrinolytic Therapy in MI

Pearl #1217 - Medicine

© Marrow Observatory - Dec 2018 - prashikatam@gmail.com

Most fibrin specific	Tenoecteplase
Least fibrin specific	Streptokinase
Shortest half-life	Alteplase
Lowest incidence of intracranial hemorrhage	Streptokinase
Fibrinolytic agent is given as a single bolus dose	Tenoecteplase

* Routine Angiography → Elective (and anytime) after thrombolysis & do in 1st 5days coz pt remains hospitalised for ≈ 5days + Insurance. If not possible financially then can be done after weeks or month.

* Follow up drugs → i) Aspirin (150mg) lifelong, Clopidogrel (75mg/day) / Ticagrelor (90mg/BD) for 1yr → Dual Anti-platelet therapy (DAPT)

ii) Atorvastatin (40mg/100) for 1-3 months then taper the dose to 10-20mg/day lifelong irrespective of the lipid profile


iii) GIIb/IIIa (infusion before & during PCI) for max 2days

iv) Anticoagulant of choice is LMW Heparin > UFH (monitor aPTT in UFH) (LMW → Anoxafarin available as pre-filled syringe 0.6ml BD sc) given

* High Intensity → Atorva (40-80mg)
→ Rosuva (20-40mg)

* Moderate int → Atorva (20-40mg)
→ Rosuva (5-10mg)

* Fenofibrate only when TG > 500 & is given along with Moderate Intensity drugs



Contraindications for the use of fibrinolytic agents

Absolute contraindications

History of cerebrovascular hemorrhage at any time

Nonhemorrhagic stroke or other cerebrovascular events within the past year

Marked hypertension (systolic pressure > 180mmHg and/or a diastolic pressure > 110 mmHg) at any time during the acute presentation

Suspicion of aortic dissection

Active internal bleeding (excluding menses)

Relative contraindications

Current use of anticoagulants (INR ≥ 2)

Recent (<2 weeks) invasive or surgical procedure

Prolonged (>10 min) cardiopulmonary resuscitation

Known bleeding diathesis

Pregnancy

Hemorrhagic ophthalmic condition (e.g., hemorrhagic diabetic retinopathy)

Active peptic ulcer disease

History of severe hypertension that is currently adequately controlled

Category 1

Use high-intensity statins irrespective of cholesterol levels in Atherosclerotic Cardiovascular diseases (ASCVD) like MI/CAD/Angina/Stroke/TIA/PVD.

Category 2

Based on cholesterol levels in patients without ASCVD

A) LDL more than 190 - high-intensity statins (moderate intensity if age more than 75 years)

B) LDL more than 70-DM+ Age more than 40 years

C) LDL more than 70 + Age more than 40 years

D) 10 years CV risk more than 7.5%

Treatment

A - high-intensity statins

B(C)/D - moderate-intensity statins

B + C(D) - high-intensity statins

High-intensity statins : Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg

Moderate-intensity statins : Atorvastatin 20-40 mg, Rosuvastatin 5-10 mg

* Fenofibrate not advocated unless TG more than 500. It can be administered along with a moderate-intensity statin.

*] NSTEMI / UA :-



i) Thrombolysis is C/I & No role of 1^o PCI \Rightarrow
Rx is same as the follow up Rx of STEMI
 \Rightarrow Tells u that pt has 2 or more Risk factors [High risk category]
consider NSTEMI pt for Elective PCI

Category	Management
High-risk (12–30%)	<ul style="list-style-type: none"> Aspirin + heparin/low molecular weight heparin (LMWH) GP IIb/IIIa antagonist Early percutaneous coronary intervention (PCI)
Intermediate risk (4–8%)	<ul style="list-style-type: none"> Aspirin + clopidogrel Unfractionated heparin (UFH) or low molecular weight heparin (LMWH) PCI
Low-risk (<2%)	<ul style="list-style-type: none"> Aspirin No heparin Observe

*] Complications of ACS :-

1) Arrhythmias :- i) VF

ii) AF

iii) Bradycardia \rightarrow Atropine may be given (0.6 - 1.2mg IV)

} Transient & usually no hemodynamic disturbance

2) Cardiogenic shock :- i) Cx of Arrhythmia, Hypovolemia (Excessive diuretics, vomiting or extensive MI)

3) LV failure :- i) Killip classification used to assess LV dysfunction & Predicting mortality risk in MI

Class I :- No signs of LV failure

Class II :- S₃ + Basal Crepitations

Class III :- Pulmonary Edema

Class IV :- Cardiogenic shock

*) ventricular remodelling can be prevented by ACE \ominus & β \ominus

} LV failure is seen in Ant wall MI \rightarrow Rx :- Revascularization \ominus PCI

*) Cardiogenic shock occurs when Infarction $\geq 40\%$ & pt. has systolic BP < 90 mm & pulm. cap. wedge pressure > 18 mm

ii) RV failure = \uparrow JVP + clear lung fields + Hypotension \Rightarrow Suspected in a patient \in Inferior wall MI \Rightarrow Rx :- \uparrow Fluids (if JVP/CVP not elevated)

iii) Forrester & Diamond classification \Rightarrow alternative to Killip classification

Simplified Forrester & Diamond hemodynamic classification in STEMI		
Class 1	No hypotension	No pulmonary congestion
Class 2	No hypotension	Pulmonary congestion
Class 3*	Hypotension	No pulmonary congestion
Class 4 *	Hypotension	Pulmonary congestion

* Include RV and Bi-Ventricular MI. ** Cardiogenic shock . www.drsvenkatesan.co.in

4) Mechanical complications \rightarrow Myocardial rupture :- M/C in first 7 days of STEMI, common in older women & M/C involves Anterior wall \rightarrow Early surgical Rx needed
 \rightarrow Rupture of Ventricular free wall :- It is M/C of all leading to Hemopericardium & cardiac tamponade
 \rightarrow Rupture of Ventricular septum :- lead to Acute VSD / Lt \rightarrow Rr. shunt \rightarrow Pansystolic murmur radiating to Lt sternal border & Kernig's \otimes
 \rightarrow Rupture of Papillary muscle :- lead to severe Mitral Regurgitation \rightarrow Pansystolic murmur \in S₃ \oplus

5) Embolism :- Infarct \rightarrow ↓ local contractility \rightarrow stasis \rightarrow Thrombus on Endocardial surface \rightarrow systemic thromboembolism

6) Ventricular Aneurysm :- Acute Anterior Transmural Infarcts \rightarrow Ventricular wall may bulge outward during Systole

7) Pericarditis \rightarrow Early :- developing on 2nd / 3rd day

\rightarrow Late (Dressler syn.) :- develops 2-10 wks after infarct coz of Immune mediated Rx against Necrotic muscle \Rightarrow Fever, pericarditis & Pleurisy
On ECG :- PR segment depression / ST-segment elevation

Rx :- Aspirin [Note :- NSAIDs or Corticosteroids impair the infarct healing process & predispose to Myocardial rupture :- These are C/I in Early Postinfarction period]

*] PCI related MI :- Elevation of cTn > 5 times normal in presence of MI & ECG changes, angiographic or imaging abnormality [even cTn rise of $> 20\%$ counts]

*] CABG related MI :- Elevation of cTn > 10 times the baseline values in presence of new pathological Q waves, angiographic / imaging abnormality

An antiproliferative agent is attached to the stent by use of a thin polymer coating. This antiproliferative drug elutes from the stent over a 1 to 3 month period after implantation.

- The **first-generation** devices were coated with either **sirolimus or paclitaxel**.
- **Second-generation** drug-eluting stents use newer agents such as **everolimus, biolimus, and zotarolimus**. These second-generation drug-eluting stents are more effective with fewer complications like stent thrombosis than the first generation stents.

Revascularization with PCI (percutaneous coronary intervention) is indicated in high-risk patients who have one or more of the following:

- New ST-segment depression
- Diabetes mellitus
- Renal dysfunction - eGFR <60mL/min per 1.73m²
- Ejection fraction <40%
- Early postinfarction angina
- PCI within the past 6 months
- Prior CABG
- Refractory angina
- Symptoms of congestive heart failure
- Hemodynamic instability
- Recurrent angina at rest/low-level activity despite treatment
- Elevated troponin T or troponin I
- Sustained VT or VF